|Articles|January 18, 2002
New CBER Guidance, Posted 9 January 2002
Author(s)BioPharm International Editors
Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Implications of the First Liquid IV Infliximab Biosimilar
2
Risks, Resource Strain, and Trade-Offs in FDA’s CNPV Pilot Program
3
Why 503B Compounding Pharmacies Choose Prefabricated POD® Cleanrooms
4
The Switch to Cell-Free DNA: Strategic and Regulatory Considerations for Advanced Therapies
5
